Phase 2 Thalassemia Clinical Trials
9 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–9 of 9 trials
Recruiting
Phase 1Phase 2
ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia
Beta-Thalassemia
Children's Hospital of Philadelphia12 enrolled1 locationNCT06364774
Recruiting
Phase 2
A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body
Non-Transfusion Dependent Beta-Thalassemia (NTDT)
Regeneron Pharmaceuticals95 enrolled26 locationsNCT06421636
Recruiting
Phase 2
Evaluating the Clinical Efficacy and Safety of Luspatercept Combined With Thalidomide in the Treatment of β-TDT Patients
Transfusion-dependent β-thalassemia Patients
Rongrong Liu78 enrolled8 locationsNCT07338344
Recruiting
Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Beta-Thalassemia
Celgene99 enrolled26 locationsNCT04143724
Recruiting
Phase 1Phase 2
An Open-label Study of a Gene Therapy Product (Vebeglogene Autotemcel) in Transfusion Dependent Beta-Thalassemia
Beta-Thalassemia
Lantu Biopharma6 enrolled2 locationsNCT06308159
Recruiting
Phase 2
A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or Low-risk Myelodysplastic Syndromes
Myelodysplastic SyndromeBeta Thalassemia Major Anemia
Pharmacosmos A/S90 enrolled1 locationNCT05693909
Recruiting
Phase 2
Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta Thalassemia
Genetic DiseaseFetal HemoglobinThalassemia Major
National Institute of Blood and Marrow Transplant (NIBMT), Pakistan54 enrolled1 locationNCT06490627
Recruiting
Phase 2
Evaluation of Recombinant Humanized Anti-CD25 Monoclonal Antibody for Preventing Graft-versus-host Disease After Haploidentical/matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Transfusion-dependent Thalassemia
Transfusion Dependent Thalassemia
Rongrong Liu396 enrolled5 locationsNCT06657391
Recruiting
Phase 1Phase 2
Thal-Fabs: Reduced Toxicity Conditioning for High Risk Thalassemia
Thalassemia in Children
The Hospital for Sick Children20 enrolled1 locationNCT05426252